Chronomedical aspects of oncology and geriatrics

Germaine Cornélissen, Denis Gubin, Francine Halberg, Gerard Milano, Franz Halberg

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Extensive laboratory evidence on the merits of cancer chronotherapy is validated by the doubling of 2-year disease-free survival rate obtained by the chronoradiotherapy of patients with very advanced perioral cancers and by the quadrupling of the 5-year survival achieved by the chronochemotherapy of patients with advanced ovarian and bladder cancer. Miniaturized monitors for marker rhythmometry of tumor and core temperature recorded over long spans should facilitate the optimization of treatment by timing, while also serving the purpose of earliest intervention. The likelihood of a cure should be increased by focusing upon the now extensively documented tumor marker rhythms that may show time structure (chronome) alterations before exceeding the physiological range (that is otherwise neglected as one of random variation), and before overt symptoms appear.

Original languageEnglish (US)
Pages (from-to)77-82
Number of pages6
JournalIn Vivo
Volume13
Issue number1
StatePublished - Jan 1 1999

Fingerprint

Geriatrics
Oncology
Tumor Biomarkers
Chronotherapy
Urinary Bladder Neoplasms
Ovarian Neoplasms
Disease-Free Survival
Neoplasms
Survival Rate
Temperature
Survival
Therapeutics

Keywords

  • Chronochemotherapy
  • Chronome
  • Chronoradiotherapy
  • Circadian
  • Circannual
  • Circaseptan

Cite this

Cornélissen, G., Gubin, D., Halberg, F., Milano, G., & Halberg, F. (1999). Chronomedical aspects of oncology and geriatrics. In Vivo, 13(1), 77-82.

Chronomedical aspects of oncology and geriatrics. / Cornélissen, Germaine; Gubin, Denis; Halberg, Francine; Milano, Gerard; Halberg, Franz.

In: In Vivo, Vol. 13, No. 1, 01.01.1999, p. 77-82.

Research output: Contribution to journalReview article

Cornélissen, G, Gubin, D, Halberg, F, Milano, G & Halberg, F 1999, 'Chronomedical aspects of oncology and geriatrics', In Vivo, vol. 13, no. 1, pp. 77-82.
Cornélissen G, Gubin D, Halberg F, Milano G, Halberg F. Chronomedical aspects of oncology and geriatrics. In Vivo. 1999 Jan 1;13(1):77-82.
Cornélissen, Germaine ; Gubin, Denis ; Halberg, Francine ; Milano, Gerard ; Halberg, Franz. / Chronomedical aspects of oncology and geriatrics. In: In Vivo. 1999 ; Vol. 13, No. 1. pp. 77-82.
@article{facf9974b632463ca85e0bd4323abd14,
title = "Chronomedical aspects of oncology and geriatrics",
abstract = "Extensive laboratory evidence on the merits of cancer chronotherapy is validated by the doubling of 2-year disease-free survival rate obtained by the chronoradiotherapy of patients with very advanced perioral cancers and by the quadrupling of the 5-year survival achieved by the chronochemotherapy of patients with advanced ovarian and bladder cancer. Miniaturized monitors for marker rhythmometry of tumor and core temperature recorded over long spans should facilitate the optimization of treatment by timing, while also serving the purpose of earliest intervention. The likelihood of a cure should be increased by focusing upon the now extensively documented tumor marker rhythms that may show time structure (chronome) alterations before exceeding the physiological range (that is otherwise neglected as one of random variation), and before overt symptoms appear.",
keywords = "Chronochemotherapy, Chronome, Chronoradiotherapy, Circadian, Circannual, Circaseptan",
author = "Germaine Corn{\'e}lissen and Denis Gubin and Francine Halberg and Gerard Milano and Franz Halberg",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "77--82",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Chronomedical aspects of oncology and geriatrics

AU - Cornélissen, Germaine

AU - Gubin, Denis

AU - Halberg, Francine

AU - Milano, Gerard

AU - Halberg, Franz

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Extensive laboratory evidence on the merits of cancer chronotherapy is validated by the doubling of 2-year disease-free survival rate obtained by the chronoradiotherapy of patients with very advanced perioral cancers and by the quadrupling of the 5-year survival achieved by the chronochemotherapy of patients with advanced ovarian and bladder cancer. Miniaturized monitors for marker rhythmometry of tumor and core temperature recorded over long spans should facilitate the optimization of treatment by timing, while also serving the purpose of earliest intervention. The likelihood of a cure should be increased by focusing upon the now extensively documented tumor marker rhythms that may show time structure (chronome) alterations before exceeding the physiological range (that is otherwise neglected as one of random variation), and before overt symptoms appear.

AB - Extensive laboratory evidence on the merits of cancer chronotherapy is validated by the doubling of 2-year disease-free survival rate obtained by the chronoradiotherapy of patients with very advanced perioral cancers and by the quadrupling of the 5-year survival achieved by the chronochemotherapy of patients with advanced ovarian and bladder cancer. Miniaturized monitors for marker rhythmometry of tumor and core temperature recorded over long spans should facilitate the optimization of treatment by timing, while also serving the purpose of earliest intervention. The likelihood of a cure should be increased by focusing upon the now extensively documented tumor marker rhythms that may show time structure (chronome) alterations before exceeding the physiological range (that is otherwise neglected as one of random variation), and before overt symptoms appear.

KW - Chronochemotherapy

KW - Chronome

KW - Chronoradiotherapy

KW - Circadian

KW - Circannual

KW - Circaseptan

UR - http://www.scopus.com/inward/record.url?scp=0344938007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344938007&partnerID=8YFLogxK

M3 - Review article

VL - 13

SP - 77

EP - 82

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -